Fish Oil · Evidence-First Sub-Page
Educational reference page covering fish-derived omega-3 (EPA + DHA) supplements — what fish oil is, where it comes from, how it is concentrated, what the human-evidence record actually shows for fish-oil-form omega-3, and how to read a label and avoid the fish-specific safety pitfalls. This sub-page sits inside the omega-3 cluster hub alongside siblings algal oil, krill oil, and flaxseed-ALA. Not medical advice.
§1 · Quick Summary (60-second read)
Fish oil is the most studied dietary source of long-chain omega-3 (EPA + DHA) in the human-trial record. The great majority of large randomized trials in the omega-3 evidence base — GISSI-Prevenzione, VITAL, STRENGTH, OMEGA-REMODEL, and Cochrane's 79-trial 2018 synthesis — used a fish-oil-derived intervention.
Three things to know before you buy:
- "Fish oil 1000 mg" is total oil per softgel, not the EPA+DHA active ingredient. A low-concentration natural-triglyceride softgel may deliver only 300 mg EPA+DHA; a high-concentration re-esterified triglyceride (rTG) softgel can deliver 700 mg from the same 1000 mg. Always read the EPA and DHA milligrams disclosed separately.
- Cardiovascular benefit is conditional, not universal. GISSI-Prevenzione (1999) showed clear post-MI mortality benefit at 1 g/day in the pre-statin era; Cochrane's 2018 synthesis of 79 trials in the statin era concluded the overall effect is small. A 4 g/day prescription pure-EPA medication (icosapent ethyl) reduced major cardiovascular events by 25% in statin-treated patients with high triglycerides (REDUCE-IT). A 4 g/day mixed EPA+DHA prescription product did not reduce events and increased atrial fibrillation risk (STRENGTH).
- Fish-specific safety risks are real and not interchangeable across the omega-3 sub-family. Cod liver oil in particular is not the same product as standard fish oil — it carries a vitamin A overdose risk and is not recommended in pregnancy.
Bottom line: Choose a third-party-certified product (IFOS, USP, or NSF) sourced from low-food-chain fish (anchovy or sardine), match the EPA+DHA dose to your reason for taking it, and read §6 before going above 3 g/day or choosing cod liver oil.
§2 · What is Fish Oil? Sources and refining
Fish oil is the lipid fraction extracted from the body tissue (or, for cod liver oil, the liver) of cold-water fish. Its principal omega-3 components are EPA and DHA, which fish acquire by eating microalgae lower in the marine food chain.
§2.1 · Marine sources at a glance
| Source | Food-chain position | Native EPA:DHA | Strengths | Concerns |
|---|---|---|---|---|
| Anchovy | Low · 1–2 yr | ~18:12 | Lowest heavy-metal load; dominant raw material for most premium concentrates (Peruvian / Chilean fisheries) | Single-fishery concentration risk (El Niño collapse years) |
| Sardine | Low · 2–3 yr | ~18:12 | Low metals; MSC-certified fisheries available | Seasonal supply; smaller volumes |
| Mackerel (mid) | Mid · 5–8 yr | ~14:14 to 18:12 | Naturally higher concentration | Heavier metals than anchovy/sardine; some Atlantic stocks under management pressure |
| Salmon (mostly farmed) | Mid–high | ~8:11 to 10:14 | Pleasant flavor; co-occurs with astaxanthin | Farmed-vs-wild omega-3 gap (wild ≈1.5–2× farmed); contaminant profile depends on region |
| Cod liver oil | Mid · 10+ yr | ~7:10 to 9:12 plus vitamin A and vitamin D | Traditional supplement with fat-soluble vitamins | ⚠️ Vitamin A overdose risk; teratogenic in pregnancy; not interchangeable with standard fish oil — see §6.3 |
| Tuna (apex) | High · 8–15 yr | DHA-dominant | High native DHA | ⚠️ Significant mercury; not recommended as raw material |
§2.2 · From crude oil to finished softgel
A typical finished softgel is several refining steps removed from a whole fish: wet rendering (cook + press) → refining (degumming, neutralization, bleaching, deodorization) → molecular distillation under high vacuum, which removes the bulk of mercury, PCBs, dioxins, and polycyclic aromatic hydrocarbons (most premium oils report contaminants below detection limits after this step) → concentration by saponification and urea complexation to produce a 50–90% EPA+DHA ethyl ester (EE) fraction → optional re-esterification of the EE concentrate onto a glycerol backbone using a lipase, producing rTG.
Reader takeaway: The EPA+DHA milligrams disclosed on the back of the label are what matter. A 1000 mg low-concentration natural-triglyceride softgel is a fundamentally different product from a 1000 mg high-concentration rTG softgel.
§3 · Form-to-shelf concentration cheat sheet
The omega-3 hub page §7 covers the chemistry and bioavailability of TG, rTG, EE, and PL forms in depth. This sub-page answers the practical question: how many softgels do you actually swallow?
| Form | EPA+DHA concentration | EPA+DHA per 1000 mg softgel | Typical product category |
|---|---|---|---|
| Natural TG (entry-level) | 25–35% | 250–350 mg | Most mass-market "1000 mg fish oil" softgels |
| 18/12 TG (standard) | 30% (180+120) | 300 mg | Many mainstream brands |
| 33/22 EE (concentrated) | 55% (330+220) | 550 mg | Mid-concentration concentrates; chemistry of generic prescription omega-3-acid ethyl esters |
| 50/20 rTG (high-end) | 70% (500+200) | 700 mg | Premium rTG concentrates |
| 70/10 rTG (EPA-rich) | 80% (700+100) | 800 mg | EPA-dominant concentrates for mood and cardiovascular support |
| Prescription icosapent ethyl | ≥96% pure EPA | 1000 mg EPA | A prescription medication (4 g/day for a specific high-risk population — see §4); not a supplement |
Softgel count to reach 2 g/day EPA+DHA (a common dose for triglyceride lowering or rheumatoid arthritis): ~7 softgels of 18/12 TG · ~4 of 33/22 EE · ~3 of 50/20 rTG · ~3 of 70/10 EPA-rich rTG. This is the most useful number to know in the supplement aisle — a high-concentration product is almost always cheaper per milligram of EPA+DHA even when the bottle price is higher, and the lower daily pill count improves adherence.
"Fish oil vs ethyl ester" is not either/or — EE is a refining form of fish oil, not a separate source. The same is true of "fish oil vs prescription omega-3": both prescription omega-3-acid ethyl esters and prescription icosapent ethyl are derived from fish oil, then concentrated and brought under medication regulation.
§4 · What the human evidence actually shows for fish-oil-form omega-3
The omega-3 hub page §4 catalogs the full cluster across cardiovascular, brain, anti-inflammatory, pregnancy, eye, mood, muscle, and skin domains. This sub-page covers the fish-specific trials.
§4.1 · The five fish-specific trials that anchor the picture
GISSI-Prevenzione (1999, Lancet; PMID 10465168) randomized 11,324 patients within three months of a myocardial infarction (factorial design) to 1 g/day n-3 PUFA, vitamin E, both, or neither. Over 3.5 years the n-3 arm showed a 15% relative reduction in the primary composite endpoint, a 20% reduction in all-cause mortality, and a 30% reduction in cardiovascular mortality — driven largely by reduced sudden cardiac death. This trial established fish oil's cardiology reputation; the population (recent MI, pre-statin-era background therapy) matters when interpreting the effect size.
OMEGA-REMODEL (Heydari 2016, Circulation; PMID 27482002) randomized 358 patients shortly after acute MI to 4 g/day omega-3 ethyl esters or placebo for six months, with cardiac MRI as the primary outcome. The high-dose arm showed reduced adverse left-ventricular remodeling and reduced non-infarct myocardial fibrosis, alongside reductions in hs-CRP and Lp-PLA2. This adds structural cardiac evidence (not just event-rate evidence) to the fish-oil-at-high-dose-post-AMI case.
Cochrane 2018 (Abdelhamid / Hooper; PMID 30019766) synthesized 79 randomized trials of long-chain omega-3 (predominantly fish oil) covering 112,059 participants over 12–72 months. The conclusion: long-chain omega-3 probably make little or no difference to all-cause mortality or cardiovascular events in the broad evidence base, with risk ratios clustered near 0.97 and most statistically non-significant. This is the most important honest-writing data point on this page: the modern statin-era base does not support universal cardiovascular benefit from low-dose fish oil in the general population. It does not contradict GISSI-Prevenzione — it places it in the context of a different therapeutic landscape.
COMBOS (Davidson 2007, Clin Ther; PMID 17825687) randomized 254 patients with persistent high triglycerides on simvastatin 40 mg/day to prescription omega-3-acid ethyl esters 4 g/day or placebo for 8 weeks. The omega-3 add-on arm showed ~30% triglyceride reduction, ~9% non-HDL cholesterol reduction, ~28% VLDL reduction, and reduced apolipoprotein B. This answers the high-frequency reader question, "I'm already on a statin — is there evidence for adding fish oil?" The evidence-supported answer for persistent high triglycerides on statin: yes, a 4 g/day prescription dose has clear lipid effects.
Schuchardt and Hahn 2013 (PLEFA; PMID 23676322) is the narrative review anchoring the form-comparison discussion. The synthesis: rTG produces plasma omega-3 incorporation superior to fasted-state EE, but a fat-containing meal largely closes that gap. This is the reference behind the hub page's "take fish oil with a meal" recommendation.
§4.2 · How these fit with the broader omega-3 cluster
Fish oil is the carrier in the majority of trials in every omega-3 benefit area on the hub page — triglyceride lowering, rheumatoid arthritis, dry-eye disease, EPA-predominant mood support, pregnancy DHA outcomes, post-MI outcomes. Hub page §4 is the authoritative cluster summary; this sub-page does not repeat it.
§5 · Dose by goal
The hub page §5 catalogs omega-3 dosing across all use cases and authoritative bodies. The fish-specific table adds the softgel-count translation:
| Use case | EPA+DHA daily dose | EPA:DHA emphasis | Softgels (worked example) | Source basis |
|---|---|---|---|---|
| General maintenance | 250–500 mg | Balanced | 1 softgel 33/22 EE; or 2 of 18/12 TG | NIH-ODS · WHO/ISSFAL · EFSA 250 mg cardiac claim |
| Triglyceride lowering (mild–mod) | 2–4 g | Balanced | ~3 of 50/20 rTG; ~4 of 33/22 EE for 2 g | Wang 2023 PMID 37264945; COMBOS PMID 17825687 |
| CV secondary prevention (statin-treated, high TG, high-risk) | 4 g pure-EPA prescription icosapent ethyl | Pure EPA | 4 prescription capsules; a medication, not a supplement | REDUCE-IT PMID 30415628 |
| Post-MI (traditional 1 g/day pathway) | 1 g | Balanced | ~3 of 18/12 TG; 2 of 33/22 EE | GISSI-Prevenzione PMID 10465168; note Cochrane 2018 modern-era weakening PMID 30019766 |
| Post-AMI cardiac remodeling (MRI-validated) | 4 g omega-3 EE × 6 mo | Balanced | ~7 of 33/22 EE; ~5 of 50/20 rTG | OMEGA-REMODEL PMID 27482002 |
| Depression (MDD adjunct) | ~1 g EPA in ≥60% EPA formulation | EPA-dominant | 1–2 of 70/10 EPA-rich rTG | Liao 2019 PMID 31383846 |
| Rheumatoid arthritis | 2.7–4 g | Slightly EPA-leaning | ~4–6 of 50/20 rTG | Wang 2024 PMID 38922552 |
| Dry-eye disease | 1–2 g | Balanced | 2–3 of 50/20 rTG | Hub page §4 dry-eye sub-cluster |
| Pregnancy | 200–600 mg DHA | DHA-dominant | Prefer low-mercury source with third-party certification; algal oil is a fish-free alternative | Middleton 2018 PMID 30480773 |
| Upper limit (FDA) | ≤3 g/day from supplements; ≤5 g/day diet + supplements | — | — | FDA 2004 GRAS |
| Upper limit (EFSA) | ≤5 g/day EPA+DHA appears safe for adult long-term intake | — | — | EFSA 2012 |
Two fish-specific dosing honesty points:
- The atrial-fibrillation signal at ≥4 g/day is real (STRENGTH ≈ +69% relative). Reaching the 4 g/day range without medical supervision is inappropriate, particularly for anyone with personal or family history of atrial fibrillation. See hub page §6.
- Cod liver oil cannot be dosed using EPA+DHA milligrams alone — its vitamin A content is often the limiting nutrient. See §6.3.
§6 · Fish-specific safety
The hub page §6 covers the omega-3 safety profile in general (bleeding, the 4 g/day AF signal, drug interactions, pregnancy, pediatrics, TOTOX oxidation). This sub-page covers the four dimensions specific to fish-derived omega-3.
§6.1 · Fish allergy and shellfish allergy — different questions
Highly refined fish oil has most fish protein removed during refining. Published evidence suggests most people with fish allergy tolerate fish oil, but the FDA still requires "contains fish" labeling — and people with a history of severe fish allergy or anaphylaxis should choose algal oil instead (no fish-protein cross-reactivity at all).
Shellfish allergy is a different question. Shellfish allergy is not triggered by fish oil — but it is a concern for krill oil (krill are crustaceans). If you have a shellfish allergy, fish oil is fine; krill oil is not. See sibling krill oil sub-page.
§6.2 · Heavy metals and persistent organic pollutants
This is the dimension that genuinely distinguishes fish oil from other omega-3 sub-family members and that justifies the existence of third-party certification.
| Contaminant | Source mechanism | Higher-risk species | Removal by modern refining | Third-party limit |
|---|---|---|---|---|
| Mercury (methylmercury) | Marine food-chain biomagnification | Tuna, swordfish, shark, king mackerel | Most premium products below detection (<0.005 mg/kg) | IFOS ≤0.1 mg/kg |
| PCBs | Legacy industrial pollution; lipid-soluble; biomagnifies | High-fat large fish; some farmed salmon | Molecular distillation removes >95% | IFOS sum ≤90 ng/g; dioxin-like PCBs ≤2 pg WHO-TEQ/g |
| Dioxins | Legacy industrial-combustion pollution; extremely persistent | High-fat large fish; Baltic salmon | Molecular distillation removes the great majority | IFOS / EFSA ≤2 pg WHO-TEQ/g |
| PBDEs / PFAS / PAHs | Industrial chemical pollution | High-fat large fish; coastal fish | Partly removed during refining | No unified ceiling yet; IFOS 5-star panel covers |
| Microplastics / plasticizers | Emerging research (2020s) | Broad food-chain exposure | Standardization pending; most premium oils below detection | GOED 2024 voluntary guidance in development |
Reader takeaways for purity:
- Prefer anchovy or sardine sourcing (short lifespan + low trophic level) over salmon or cod (mid) over tuna / shark / swordfish (apex; not recommended).
- Prefer products carrying a third-party certification mark — IFOS 5-star, USP Verified, or NSF.
- Prefer products labeled molecularly distilled (or "short-path distilled").
- Avoid vague sourcing ("marine oil" with no species disclosed), no third-party certification, and no per-softgel EPA+DHA milligram disclosure.
§6.3 · Cod liver oil and vitamin A — a separate warning, not a footnote
Cod liver oil is extracted from cod liver, not from cod body tissue, so it concentrates the fat-soluble vitamins the liver stores. A typical serving carries approximately 800–3000 µg RAE of vitamin A and 10–50 µg of vitamin D, depending on the product.
Why this matters:
- The adult Tolerable Upper Intake Level for vitamin A is 3000 µg RAE per day from all sources combined. A serving of cod liver oil plus a multivitamin can exceed this easily.
- High vitamin A intake in pregnancy is teratogenic. The classic Rothman 1995 NEJM analysis associated >3000 µg RAE/day in early pregnancy with neural-tube and craniofacial defects. Cod liver oil at high doses is not recommended in pregnancy.
- Chronic vitamin A overdose can cause hair loss, dry and cracking skin, hepatotoxicity, increased bone resorption with fracture risk, and raised intracranial pressure.
Practical guidance:
- Cod liver oil is distinct from standard fish oil and should not be substituted for it without checking the vitamin A µg RAE per serving.
- If you choose cod liver oil, do not stack it with a multivitamin or other supplement that also contains vitamin A.
- If you are pregnant, planning to become pregnant, or breastfeeding, prefer a standard EPA + DHA fish oil (or algal oil) with disclosed mercury and PCB testing, and discuss any cod-liver-oil use with your prenatal-care provider.
§6.4 · The atrial-fibrillation signal at ≥4 g/day
As covered in hub page §6, STRENGTH (PMID 33190147) showed ~69% relative increase in atrial fibrillation in the 4 g/day mixed EPA+DHA arm; the 4 g/day pure-EPA arm in REDUCE-IT (PMID 30415628) also showed a smaller AF signal. The American Heart Association now flags this in any guidance covering doses in this range. People with personal or family history of atrial fibrillation should reach the 4 g/day range only under medical supervision and should be monitored. This is not a concern at the 250 mg–1 g/day general-maintenance range.
§7 · How to choose quality fish oil
The hub page §9 details the broader quality and sustainability framework. This sub-page distills it into an aisle-ready checklist.
§7.1 · Ten things to check on a fish-oil label
| # | Check | What to look for |
|---|---|---|
| 1 | Species disclosed | Anchovy or sardine preferred; vague "marine oil" without species is a warning |
| 2 | EPA + DHA mg per softgel | Must be disclosed separately; "fish oil 1000 mg" alone is not enough |
| 3 | Form (TG / rTG / EE) | Explicit; premium rTG usually states "natural triglyceride form" or "re-esterified triglyceride" |
| 4 | Third-party certification mark | IFOS 5-star, USP Verified, NSF Sport (MSC = sustainability, not purity) |
| 5 | Molecular distillation | "Molecularly distilled" or "purified by molecular distillation" |
| 6 | TOTOX value disclosed | ≤26 per GOED; ≤10 indicates a fresh oil |
| 7 | Manufacture / best-by date | Avoid product close to best-by; omega-3 is highly unsaturated and oxidizes |
| 8 | Packaging | Dark glass with cool-storage guidance; blister-packed softgels protect freshness better than loose bulk |
| 9 | Antioxidant added | Mixed tocopherols and/or rosemary extract slow oxidation |
| 10 | GMP / cGMP manufacturing | A basic quality baseline |
§7.2 · Sustainability hierarchy
In rough order of preference for a reader who cares about ocean health: MSC-certified anchovy or sardine (low trophic, certified fishery, lowest heavy-metal load) > algal oil (fermentation-based, no wild fishery — see sibling algal oil sub-page) > uncertified large-fish-source fish oil (not recommended on either purity or sustainability grounds).
§7.3 · Seven ways to manage fishy reflux and burp-back
The most common reason people stop taking fish oil is the aftertaste. Most of it is preventable: (1) take it with a fat-containing meal — the single most effective fix; (2) refrigerate the bottle and consider taking softgels cold; (3) choose a high-purity, low-TOTOX product (oxidized oil is the main culprit); (4) choose enteric-coated softgels if reflux persists; (5) choose a higher-concentration rTG so total daily oil volume is lower; (6) split the dose (2 softgels twice a day instead of 4 at once); (7) switch to algal oil — the fall-back for users with persistent reflux. See sibling algal oil sub-page.
§8 · Fish oil vs algal vs krill vs flax — when to pick which
| Source | Best fit | Sub-page |
|---|---|---|
| Fish oil | Cost-efficient EPA + DHA delivery; deepest human-trial base; most adults | this page |
| Algal oil | Vegan / vegetarian; severe fish allergy; pregnancy with strong purity preference; readers averse to fish taste | algal oil → |
| Krill oil | Phospholipid-form preference and astaxanthin co-occurrence; lower per-capsule EPA+DHA and higher per-mg cost; not for shellfish-allergic readers | krill oil → |
| Flaxseed-ALA | Plant-based omega-3 contribution; cannot substitute for EPA + DHA on outcomes requiring long-chain forms (adult ALA→DHA conversion <5%) | flaxseed-ALA → |
For the full omega-3 mechanism, benefits cluster, dosing framework, safety, and forms chemistry, return to the omega-3 cluster hub.
§9 · Frequently Asked Questions
The questions below are the most-searched questions on fish oil across general web search and AI assistants. Answers reflect the evidence cited throughout this page and are intentionally concise; deeper detail lives in the relevant sections above.
1. Is fish oil safe to take daily?
For most healthy adults, yes — at 250–500 mg/day EPA+DHA from a third-party-certified product. Take with a meal. Doses ≥4 g/day have been associated with increased atrial fibrillation risk and should be used under medical supervision.
2. What is the best fish oil brand?
This page does not recommend brands. The evidence-based criteria are: third-party certification (IFOS 5-star, USP Verified, NSF), molecular distillation, anchovy or sardine sourcing, transparent per-softgel EPA + DHA mg disclosure, and TOTOX ≤26. Any product meeting all of these is a defensible choice.
3. What is the difference between fish oil and prescription omega-3?
Both prescription omega-3-acid ethyl esters and prescription icosapent ethyl are derived from fish oil that has been further concentrated and brought under medication regulation. Differences: concentration (≥96% pure EPA in icosapent ethyl), specified clinical indications (statin-treated patients with high triglycerides, in REDUCE-IT), and the requirement for a physician's prescription.
4. Why does my fish oil make me burp it back up?
Usually a sign of taking it on an empty stomach or using an oxidized product. Take with a fat-containing meal; choose a high-purity low-TOTOX product; refrigerate the bottle; consider enteric-coated softgels; consider a higher-concentration rTG; or switch to algal oil. See §7.3.
5. Is fish oil safe in pregnancy?
Standard EPA + DHA fish oil at 200–600 mg/day DHA is recommended in many pregnancy-nutrition guidelines, with Cochrane (PMID 30480773) supporting DHA's role in reducing early preterm birth. Choose a low-mercury source with third-party certification. Cod liver oil is a different story — its vitamin A content is teratogenic at high doses and it is not recommended in pregnancy. Algal oil is a fish-free alternative.
6. What is the difference between cod liver oil and regular fish oil?
Regular fish oil is extracted from body tissue; cod liver oil is extracted from cod liver, which naturally concentrates vitamins A and D. Cod liver oil carries a substantial vitamin A dose that can exceed the safe upper limit if stacked with multivitamins, and is teratogenic in pregnancy at high doses. See §6.3. They are not interchangeable.
7. Are mercury and PCBs a real concern with fish oil supplements?
The raw-material risk is real — high-trophic-level fish accumulate mercury and persistent organic pollutants. The finished-product risk is mitigated by modern refining: molecular distillation removes most contaminants, and IFOS / USP / NSF testing verifies. Choose anchovy or sardine sourcing, third-party certification, and molecular-distillation disclosure.
8. What is the difference between fish oil triglyceride and ethyl ester?
TG is the natural ester form fish oil arrives in from the fish. EE is a more concentrated form created during refining (50–90% EPA+DHA per gram). rTG re-attaches the concentrated EE to a glycerol backbone, recovering most of the bioavailability advantage of natural TG at the higher concentration. With a fat-containing meal, the bioavailability difference between TG, rTG, and EE is small (Schuchardt and Hahn 2013, PMID 23676322). See §3.
9. Can I take fish oil with my blood thinner?
At general-maintenance doses (≤1 g/day), most evidence does not show clinically meaningful bleeding interactions with anticoagulants or antiplatelets. At higher doses (≥2 g/day) and in combination with anticoagulants, inform your prescribing physician and be monitored. See the omega-3 hub page §6.
10. Does fish oil really prevent heart disease?
The honest answer distinguishes populations and doses. In statin-treated patients with elevated triglycerides, 4 g/day pure-EPA prescription reduced major events by 25% (REDUCE-IT, PMID 30415628). In post-MI patients in the pre-statin era, 1 g/day fish oil reduced mortality (GISSI-Prevenzione, PMID 10465168). In the broad 79-trial Cochrane synthesis in the statin era, low-dose long-chain omega-3 made little or no difference (PMID 30019766). In a general adult population, 1 g/day did not reduce events over 5.3 years (VITAL, PMID 30415637). The truthful summary: in specific high-risk, high-triglyceride, statin-treated populations the evidence supports targeted use; in the general adult population, fish oil does not appear to prevent cardiovascular disease at low-to-moderate doses.
Cluster Sibling Sub-pages
This sub-page sits inside the omega-3 cluster hub. The sibling sub-pages cover the other omega-3 sources:
- Algal Oil — Plant-based · original dietary source of DHA · pregnancy/vegan preferred · fish-free alternative for severe fish allergy
- Krill Oil — Phospholipid form · co-occurring astaxanthin · lower per-capsule EPA+DHA · NOT suitable for shellfish-allergic readers
- Flaxseed / ALA — Plant-based ALA · adult conversion to long-chain EPA+DHA <5% · cannot substitute for long-chain forms
Tags
Body Systems: Cardiovascular · Neurological & Cognitive · Vision · Immune System · Mood & Stress Response
Mechanisms: NF-κB signaling inhibition · Specialized pro-resolving mediators (SPMs) biosynthesis · Cell membrane phospholipid integration · PPAR-α activation · GPR120 receptor activation · Competitive metabolism with arachidonic acid
Evidence Tier: Meta-analysis supported
Dosage Range: 250-500 mg/d EPA+DHA (general) · 2-4 g/d (triglyceride lowering / RA) · 4 g/d prescription pure-EPA icosapent ethyl only under physician supervision
Last Evidence Review: 2026-05-24 · Reviewed by Evidence Synthesis Lead + Regulatory Compliance Lead
Parent Hub: Omega-3 (EPA / DHA / ALA) cluster hub
Related Goals
Related Lifestyles
Related Ingredients
§10 · References
All fish-specific PMIDs verified by upstream Scita evidence document (2026-05-24). Effect sizes are reported as published. For the full 18-PMID omega-3 cluster evidence inventory (REDUCE-IT, VITAL, STRENGTH, Middleton pregnancy, Wang triglyceride, Wang RA, Liao depression, etc.), see the omega-3 cluster hub page.
Fish-specific PMIDs cited on this page
- PMID 10465168 · GISSI-Prevenzione Investigators (1999) · "Dietary supplementation with n-3 PUFA and vitamin E after myocardial infarction" · Lancet 354:447–455 · n=11,324 post-MI · 1 g/d · all-cause mortality -20%, CV mortality -30%
- PMID 27482002 · Heydari B et al. (2016) · "Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute MI" (OMEGA-REMODEL RCT) · Circulation 134(5):378–391 · n=358 post-AMI · 4 g/d × 6 mo · reduced adverse LV remodeling + non-infarct fibrosis (cardiac MRI)
- PMID 30019766 · Abdelhamid AS, Hooper L et al. (Cochrane 2018) · "Omega-3 fatty acids for primary and secondary prevention of cardiovascular disease" · Cochrane Database Syst Rev 7:CD003177 · 79 RCTs · n=112,059 · low-dose long-chain omega-3 probably little/no difference on all-cause mortality or CV events
- PMID 17825687 · Davidson MH et al. (COMBOS 2007) · "Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients" · Clin Ther 29(7):1354–67 · n=254 · TG -30%, non-HDL-c -9%, VLDL -28%, apoB ↓
- PMID 23676322 · Schuchardt JP, Hahn A (2013) · "Bioavailability of long-chain omega-3 fatty acids" · Prostaglandins Leukot Essent Fatty Acids 89(1):1–8 · rTG > EE fasted; fat-containing meal narrows the gap
Hub-page cross-link (18 additional PMIDs)
For REDUCE-IT (PMID 30415628), VITAL (PMID 30415637), STRENGTH (PMID 33190147), Middleton 2018 DHA in pregnancy (PMID 30480773), Wang 2023 triglyceride meta-analysis (PMID 37264945), Wang 2024 rheumatoid arthritis (PMID 38922552), Liao 2019 EPA depression (PMID 31383846), and the full 18-PMID omega-3 evidence inventory, see the omega-3 cluster hub page.
Regulatory and Public-Health References (not counted in PMID total)
- FDA 2004 · Qualified health claim for EPA+DHA and coronary heart disease (≥0.8 g per serving) · ≤3 g/day supplement guidance
- EFSA 2012 · Tolerable upper intake up to ~5 g/day EPA+DHA in adults
- IFOS · Third-party fish-oil purity standard (mercury ≤0.1 mg/kg · PCBs sum ≤90 ng/g · dioxin-like PCBs ≤2 pg WHO-TEQ/g · TOTOX ≤26)
- USP Verified · NSF Sport · Independent quality and purity verification programs
- GOED Voluntary Monograph · TOTOX ≤26 · peroxide value ≤5 mEq/kg · contaminant limits · microplastics guidance in development
- AHA 2017 Scientific Statement · omega-3 bleeding risk · no clinically important bleeding demonstrated at supplemental doses
- Rothman et al. (1995) · NEJM · >3000 µg RAE/day vitamin A in early pregnancy associated with neural-tube and craniofacial defects (cod liver oil context · §6.3)
Educational Disclaimer
This page is educational content and not medical advice. It does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider for individual recommendations, especially if you are pregnant, breastfeeding, on prescription medication, or managing a chronic condition. Brand and product names are not endorsed; the criteria described are evidence-based generic standards (third-party certification, molecular distillation, low-trophic-level sourcing, transparent EPA+DHA mg disclosure) that any compliant product can meet.